Before I became a "millionaire," I developed an anal fistula

Introduction"I want to become a millionaire."If you are an investor, you have probably thought about this at least once, ...
MyChesCo

J&J’s Tremfya Sustains Crohn’s Remission Through 48 Weeks

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its Crohn’s disease treatment Tremfya sustained or improved ...

長岡京病院、出産時の会陰損傷に関する42例の症例分析を報告、英文誌「Journal of the Anus, Rectum and Colon（JARC）」に掲載

［株式会社セントラルメディエンス］損傷形態を3分類し、会陰体再建術の症例を解析株式会社セントラルメディエンス（本社：東京都港区、代表取締役：中川隆太郎）のグループ医療法人である医療法人総心会 長岡京病院（所在地：京都府長岡京市、理事長：村上耕一郎）の外科チームは、経腟分娩時の会陰損傷を原因とする肛門括約筋不全（便失禁）に対し「会陰体再建術」を行った42例の治療分析をまとめました。本研究論文は、日本 ...
BIOENGINEER

Twenty-Year Groin Abscesses Traced to a Rare Appendiceal Fistula

A 64-year-old man’s recurrent groin abscesses were traced to chronic appendiceal perforation and a cecal–abdominal wall ...
StreetInsider.com

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

The cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining at surgery in a high-risk, locally ...
EuropaWire

Johnson & Johnson reports sustained TREMFYA fistula remission through 48 weeks in Phase 3 Crohn’s disease study

Johnson & Johnson has announced Week 48 results from the Phase 3 FUZION trial of TREMFYA (guselkumab) in adults with Crohn’s disease and perianal fistula. Combined fistula remis ...
RTTNews

Johnson & Johnson Reports Positive 48-week Data From TREMFYA Study In Crohn's With Perianal Fistula

Drug major Johnson & Johnson ( JNJ) announced Monday positive one-year results from the Phase 3 FUZION study, which showed TREMFYA (guselkumab) maintained or improved fistula remission through 48 ...

Johnson & Johnson Says Phase 3 Trial Results Show Tremfya Delivered Fistula Remission in Crohn's Disease

Johnson & Johnson (JNJ) said Monday one-year data from a phase 3 study showed Tremfya kept or improved fistula remission through 48 weeks in adults with Crohn's disease. The results follow previously ...

Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula

New TREMFYA® (guselkumab) 3-year as-observed data show clinical remission rates of up to 94% (172/183 patients) and endoscopic remission rates of up to 52% (89/172 patients) in adults with moderate to ...

Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula

Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistul ...
Morningstar%2c Inc.

New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

Expanding on previously reported results in the overall population, new prespecified subgroup analyses showed greater Week 24 combined fistula remission with TREMFYA versus placebo among:1 Adverse ...